Min-Chul Park
Direttore/Membro del Consiglio presso ZYVERSA THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/05/2024
Posizioni attive di Min-Chul Park
Società | Posizione | Inizio | Fine |
---|---|---|---|
ZYVERSA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/12/2022 | - |
Independent Dir/Board Member | 01/12/2022 | - | |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Direttore/Membro del Consiglio | - | - |
Inje University | Corporate Officer/Principal | - | - |
Storia della carriera di Min-Chul Park
Precedenti posizioni note di Min-Chul Park
Società | Posizione | Inizio | Fine |
---|---|---|---|
CURE BIO Co., Ltd.
CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Direttore/Membro del Consiglio | 01/10/2020 | 01/04/2022 |
Amministratore Delegato | 01/10/2020 | 01/04/2022 | |
Neomics Co., Ltd.
Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - |
Formazione di Min-Chul Park
Seoul National University | Doctorate Degree |
Statistiche
Distribuzione geografica
Corea del Sud | 5 |
Stati Uniti | 3 |
Posizioni
Director/Board Member | 5 |
Chief Executive Officer | 3 |
Doctorate Degree | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ZYVERSA THERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Neomics Co., Ltd.
Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Health Technology |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Health Technology |
CURE BIO Co., Ltd.
CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Health Technology |
- Borsa valori
- Insiders
- Min-Chul Park
- Esperienza